Meningitis is an inflammatory disease which is caused by infection due to bacteria, viruses, parasites, and fungi. It can also occur due to autoimmune diseases and certain medications. The infections due to bacteria first attack the upper respiratory tract and then passes to the brain through blood. Pneumococcal meningitis is caused by Streptococcus pneumonia and meningococcal meningitis occurs due to Neisseria meningitides infection. Viral meningitis is generally caused by enteroviruses that enter the body through the oral cavity and reach the brain. Enteroviruses generally found in saliva, mucus, and feces and transfer from one person to another person through direct contact. Sanofi SA is in the process of developing MenACYW conjugate vaccine for the treatment of meningitis. The University Hospital Inselspital, Berne is in the process of developing daptomycin as a cell wall synthesis inhibitor for the treatment of meningitis. Some of the companies having the pipeline of meningitis include Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., Sanofi SA, GlaxoSmithKline plc, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.